| Prev Close | 22.40 |
| Open | 22.40 |
| Day Low/High | 21.88 / 22.67 |
| 52 Wk Low/High | 7.26 / 22.99 |
| Volume | 1.70M |
| Avg Volume | 1.73M |
Latest News
First Week Of February 15th Options Trading For Iovance Biotherapeutics (IOVA)
Investors in Iovance Biotherapeutics Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA options chain for the new February 15th contracts and identified the following call contract of particular interest.
2 Promising Biotech Stocks That Insiders Are Snapping Up
Shares of Iovance Biotherapeutics and Reata Pharmaceuticals took it on the chin in the fourth quarter, but both companies seem ready to reward shareholders for their patience.
Here's a Handful of Small Biotechs Where Insiders Are Buying
Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.
A Lesson to Learn From Thursday's Market Action
You don't have to be Sigmund Freud to understand the psychology here.
Magellan Midstream, Xylem, Boston Scientific: 'Mad Money' Lightning Round
Jim Cramer takes a closer look at Magellan Midstream Partners, Xylem, Boston Scientific, Karyopharm Thereapeutics, Iovance Biotherapeutics, Casella Waste Systems and more.
How to Handle the Fed: Cramer's 'Mad Money' Recap (Wednesday 6/13/18)
Jim Cramer says higher rates always trigger rotations. Here's what investors should expect.
First Week Of IOVA July 20th Options Trading
Investors in Iovance Biotherapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA options chain for the new July 20th contracts and identified the following call contract of particular interest.
Small-Cap Stocks Lead the Way
As interest rate fears ease slightly, indexes rebound.
4 Small Speculative Names on My Radar
While I'm waiting for some index excitement I'm focused on trades in individual stocks.
Lennar Is One of 6 Stocks Poised to Change Direction
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Iovance Biotherapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results And Provides Corporate Update
Company to Host Conference Call at 4:30pm ET Today
Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., To Its Board Of Directors
Industry Veteran Brings Significant Clinical, Commercial, and Business Experience
IOVANCE INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of Iovance Biotherapeutics, Inc. - IOVA
Former Attorney General of Louisiana, Charles C. Foti, Jr.
Sound Familiar? Dovish Fed Talk Induces Stock Reversal
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI
Here's what you need to know now for Wednesday, Feb. 14.
Biotech Heats Up as Fear of Missing Out Returns
It's hard to believe the bounce will continue to run in V-shaped fashion.
Focused on Two Sectors
If we have a little consolidating action here the buyers will start pushing again.
5 Top Stocks With 100% Buy Ratings Right Now
These five 'Strong Buy' stocks boast a double whammy of only buy ratings and big upside potential. After the market's recent plunge, this list is quite handy.
Markets Face Heavy News Flow in Next 48 Hours
In addition to the State of the Union address and the Fed interest rate decision, companies representing about 25% of the Nasdaq 100's market cap will report results in the next two days.
'Normal' Market Selloff Feels Much Worse Than It Really Is
While painful to longs, the market will be better for it.
This Market Badly Needs a Rest
It would be a longer-term positive if the overbought conditions are alleviated.
Building in Biotech, Adding to Twitter
The challenge of this market is to keep finding new buy entries as more and more stocks become extended.
Market Gets a Little Bumpy, but Stock-Picking Still Rocks
Only when the picking worsens will I start to worry.
Biotech Looks Good and I'm Buying
The sector has been a great trading group lately and I bought these 2 names this morning.